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Abstract

Autologous platelet gel(APG)is already being used in clinical cases, as are other
blood products such as fibrin glue and platelet lysate. Fibrin sealants have been show to
stop capillary seepage and so reduce occurrences of hemotoma and edema, while
platelets have been shown to contain a host of growth factors that promote healing
including TGF-p,PDGF,lGF-1, TNF,and FGF. Platelet gel combines the hemostatic
properties of fibrin glues with the growth factors contained in platelets. By harvesting
the platelet-rich plasma from autologous blood, the risks of viral transmission and tissue
incompatibility that are often associated with blood products are eliminated effectively
and economically. The beneficial effects of APG have been documented in bum cases
and face-lift procedures, which are prone to edema and hematoma. Very little
information is available about APG’s affect on wounds in diabetic patients, though
clinical studies showed applying platelet lysate healed chronic wounds that conventional
treatments could not. Diabetic wounds are slow to heal, produce weaker scars, and often
become chronic. These chronic wounds often lead to extensive tissue damage,
osteomyelitis, and eventually amputation.
This paper relates the findings oftwo APG studies on the tensile strength of
incisional wounds. The first, carried out in healthy Spraque-Dawley rats, showed no
difference caused by the APG. The second used Zucker rats whose homozygous
genotype (fa/fa) models human type 2 diabetes. APG showed no significant effects on the
tensile strength of fa/fa rats. However, non-diabetic Zucker rats receiving APG revealed
a significant decrease in tensile strength. This unusual result is partially attributed to the
biphasic effects of growth factors such as TGF-P,IGF-1, and TNF. Future excisional
wound studies will provide a model of diabetic wounds commonly found in the clinical
arena. Histological examination ofthese models will provide needed information on the
synergistic effects of growth factors in healing-compromised wounds.
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Background
The concept of wound healing has changed dramatically in the last three decades.
It has advanced beyond simply ensuring the normal healing rate by maintaining an
aseptic wound environment with an adequate supply of blood and oxygen(Hunt, 1990).
By unraveling the machinery of growth, it is becoming possible to manipulate healing
directly at the cellular level. Hunt(1990)demonstrates that the old polar paradigm of
“healed or not” is no longer adequate, because as more is understood ofthe repair
process, it is increasingly difficult to declare when a wound is “healed”.
Instead, a healing wound is now described as progressing through eight main
components of repair: coagulation, inflammation, fibroplasia, matrix deposition,
angiogenesis, epithelization, contraction and remodeling. Following repair, remodeling
of the wound may continue for well over a year(Hunt, 1990; Kiritsy and Lynch, 1993).
In light of the growing understanding ofcellular and chemical mechanisms of healing,
this artificially linear progression over-simplifies a complex and continuous process in
which the stages overlap considerably(Hunt, 1990).
This process goes far beyond hemostasis and wound closure, beginning as soon as
the wound is inflicted and continuing long after the wound appears to be “healed”. Fibrin
and platelets are the key players in the first stage, coagulation. Circulating fibrinogen is
polymerized by thrombin and calcium into fibrin, forming a fibrous mesh trapping
platelets and red blood cells to form the clot. While providing the basis ofthe clot, fibrin
and the peptide by-products of its polymerization also attract inflammatory cells,
beginning with neutrophils followed by other leukocytes(Knighton et all982). Platelets
entering a wound,release a number of growth factors such as transforming growth factor-
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beta(TGF-p), platelet-derived growth factor(PDGF),insulin-like growth factor-1
(IGF-1), interlukin-1 (IL-1), tumor necrosis factor(TNF),and other chemical messengers
into the site of the wound (Kiritsy and Lynch, 1993; Hunt, 1990).
Growth factors are a class of cytokines, proteins used for communication between
cells, that specifically stimulate cellular replication. Many have other functions in
addition to their role as mitogens(Greenhalgh, 1996). They act both individually and
synergistically with each other (Kiritsy and Lynch, 1993). Other leukocytes such as
macrophages, lymphocytes and granulocytes are summoned by PDGF and TGF-P along
with fibrin and its by-product peptides. By the third day, macrophages are the dominant
leukocytes in the wound and from there on out govern the repair through the release of
their own growth factors(Knighton et al., 1982; Hunt, 1990).
During the inflammation stage, macrophages and, to some extent, other
inflammatory cells begin to direct repair stimulating angiogenesis and scar formation.
TGF-p suppresses mitosis within the wound while PDGF is a mitogen for smooth muscle
cells and fibroblasts at the wound edge and stimulates them to crawl from the edge of
undamaged tissue into the wound bed(Hunt, 1990; Greenhalgh, 1996). This production
of new fibroblast outside the wound and their migration into the wound is termed
fibroplasia and begins roughly 24 hours after wounding(Knighton et al., 1982).
Once fibroblasts migrate into the wound,the fourth stage of healing begins as
fibroblasts deposit granulation tissue reestablishing the extracellular matrix(Knighton et
al., 1982; Hunt, 1990). This extracellular matrix is made up initially offibronectin and
glycosaminoglycan(GAG),hyaluronic acid, and an increasing amount of collagen
including types I, II, V as the wound ages (Kiritsy and Lynch, 1993). TGF-p is the most
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powerful initiator of fibroblasts’ production offibronectin and collagen. TGF-P also
inhibits the production of collagenase, an enzyme that degrades collagen. Collagenase is
detrimental early on in matrix deposition but plays an important role in remodeling later.
PDGF stimulates production of GAG,but alone it has little effect on collagen production.
However, combined with IGF-1, PDGF substantially increases collagen production
(Kiritsy and Lynch, 1993).
As fibroblasts reestablish the continuity ofthe extracellular matrix, endothelial
cells also begin to establish new blood vessels. With in 48-72 hours, angiogenesis begins
(Hunt, 1990). Once fibroblasts begin to reestablish the extracellular matrix,
reepithelialization occurs as epithelial cells crawl over this matrix into the wound.
PDGF,TGF-p and IGF-1 all are chemotaxic for epithelial cells accelerating
reepithelialization (Hunt, 1990). Almost simultaneously contraction ofsmooth muscle
cells and collagen fibrils within the wound draw the surrounding tissues into the bed,
decreasing the area left to be filled with new tissue(Ehrlichman et al., 1991). While
contraction allows for faster closure ofthe wound by decreasing the amount oftissue to
be replaced, it may also lead to impaired function or disfigurement in some cases. PDGF
and TGF-p both decrease wound contraction and increase the rate oftissue replacement
producing a more functional scar(Saba et al., 2002; Kiritsy and Lynch, 1993).
The final stage of wound healing, remodeling, involves undoing some of what
the other stages have established. Fibronectin and GAG are largely replaced with
proteoglycans adding greater resiliency to the scar. Type III collagen, initially in high
concentration, is degraded by collagenase while PDGF and IGF-1 along with TGF-P
stimulate its replacement with type 1 collagen, which has more cross-links and so
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increases tensile strength to a maximum of70% of undamaged skin (Kiritsy and Lynch,
1993).
The application of exogenous growth factors, or those originating outside ofthe
wound, has been shown experimentally and clinically to improve healing. Using
recombinant PDGF,Saba and colleagues(2002)showed a decrease in healing time for
both a rat model and a human clinical study. TGF-p was shown by Mustoe et al.(1987)
to greatly increase the tensile strength of incisional scars in rats. Greenhalgh(1996)
points out that while the results in healthy individuals may be statistically significant,
they have not proved clinically important. The benefits of exogenous growth factors are
small to normal individuals and may even decrease the rate of healing. The effects of
TGF-P, TNF,and IL-1 have been shown to be biphasic meaning that they are beneficial
in low concentrations but harmful in high concentrations(Kiritsy and Lynch, 1993; Hunt,
1990). As more is understood about growth factors, this same biphasic action is likely
found in others as well.
However, growth factors have proved useful in healing-impaired individuals.
Using a mixture of growth factors fi*om lysed autologous platelets, Knighton et al.(1990)
treated 32 chronic cutaneous ulcers, showing substantial improvement, healing 81% of
the treated group and only 15% ofthe placebo group. Steed and co-workers(1991)
demonstrated improved healing in diabetic wounds using a similar platelet releasate from
homologous sources.
Diabetes mellitus is a major cause ofimpaired healing and chronic wounds.
Diabetic patients exhibit decreased performance ofleukocytes with less chemotaxis and
phagocytosis. Increased blood viscosity caused by high glucose levels decreases
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circulation through the microvasculature. Neuropathy, a common condition in diabetics,
allows damage and ulceration to often go unnoticed and untreated(Ehrlichman et al.
1991).
While the pathophysiology of diabetic wounds is not fully understood, animal
models have been developed with characteristics similar to human diabetes(Kiritsy and
Lynch, 1993). The Zucker fa/fa rats have been used to model obesity and noninsulin
dependent diabetes mellitus. Because oftheir homozygous recessive genotype,fe/fa.
they are genetically obese and diabetic. Though they exhibit varying levels of
hyperglycemia, the fa/fa rats display glucose intolerance, hyperinsulinemia, hyperphagia,
hyperlipidemia, and insulin resistance (Peterson et al, 1990; Smith and Czech, 1983).

Introduction
As understanding of the stages of wound healing and the factors controlling them
expands, clinicians are increasingly able to harness them as tools for improved healing.
One ofthese tools is fibrin glue made fi*om a concentration of human or bovine
fibrinogen. When activated by thrombin and calcium, and applied to a wound,the
fibrinogen polymerizes to form a fibrin clot with in seconds. Also known as fibrin tissue
adhesive(FTA)or fibrin sealant, it has been shown to be successful in curbing diffuse
bleeding and lymphatic seepage (Silver et al., 1995). It can be applied from a syringe or
can be sprayed over a raw area such as a bum or abrasion to seal capillaries and prevent
fluid loss. Surgeons have successfully used sprayed-on fibrin adhesive as a sealant to
prevent hemotomas and seromas beneath the skin offace-lift patients(Oliver et al., 2001;
Marchac et al., 1994).
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Many of the growth factors that play key roles in wound healing are stored in
platelets including TGF-p, PDGF,IGF-1, TNF,and FGF as previously mentioned (Hunt,
1990; Kiritsy and Lynch, 1993). When a wound occurs platelets not only help reestablish
hemostasis but also release these stored growth factors that initiate and govern the
healing process. Building on this concept, Knighton et al.(1986,1993)applied platelet
releasate, lysed platelets and their growth factors, to non-healing wounds with great
success. The platelets were attained as platelet-rich plasma(PRP)separated from whole
blood by centrifugation (Knighton et al., 1982). These studies also demonstrated the
wound-enhancing growth factors contained platelets, even in autologous PRP attained
from healing-compromised patients such as diabetics.
Other research has demonstrated the effects ofindividual growth factors also
improve healing. PDGF was shown to decrease healing time by Saba and associates
(2002) while Mustoe and collogues(1987) demonstrated that TGF-P increased tensile
strength. However, many growth factor effects depend on synergy among various factors
that is lost when applied separately (Kiritsy and Lynch, 1993).
Platelet gel combines hemostastic and tissue adhesive properties offibrin glue and
the healing-enhancing growth factors contained in PRP. During centrifugation, a white
band known as the buffy coat forms directly below the PRP layer and contains a high
number of leukocytes and platelets(Gentry, 1992). The buffy coat is included with PRP
in the production of platelet gel because ofthe high number of platelets and because the
added leukocytes give the inflammatory stage an initial boost. Compared to levels in
circulating blood, the small amount offibrinogen released from activated platelets does
not make a major contribution to fibrin formation (Gentry, 1992). For this reason
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fibrinogen is added to the PRP to cause quick solidification or gelling through clotting
just as any other FTA.
Heterologous sources of human blood products carry the potential risk of viral
transmissions such as human T-cell leukemia/lymphoma virus type I and II, hepatitis B
and C, and HIV (Oliver, 2001). Autologous platelet gel(APG)is made fix)m plasma
taken from the recipient’s own blood providing a safe, inexpensive way to eliminate viral
risks while maintaining effectiveness(Hartman, 1992). Clinical anecdotes have reported
decreased healing times for bums and abrasions(Hannon,2000). However, little has
been done to explore the effects of APG in chronic wounds with impaired healing
capabilities such as diabetic ulcers. The effects ofPDGF,TGF-p,PRP,and FTA have
been demonstrated (Mustoe et al., 1987; Knighton et al., 1990; Marchac et al., 1994).
Knighton and associates(1986) demonstrated PRP ability to help heal chronic wounds,
58% of which were diabetic in this study. However,little more than anecdotal evidence
is available for APG and diabetic wounds.
This paper addresses this informational gap with two studies on the tensile
strength (force/area^) of incisional wounds healed by primary closure. The first, a pilot
with healthy Sprague-Dawley rats served primarily to develop the techniques of
harvesting, processing, and applying APG and to determine any detrimental effects of
pooling individual blood samples. Scars of treated rats were hypothesized to have greater
tensile strengths than control rats. No immunological complications were expected in
either study because each rat strain is inbred. A single application of APG in each study
was hypothesized to significantly affect the tensile strength ofthe resulting scars.
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The second examined the effect of APG on Zucker(fa/fa)fat rats, a model for
type 2 diabetes. Non-diabetic lean Zucker rats were included to determine ifthe effects
on tensile strength resulted from the treatment with APG,the type ofrat, or a
combination of the two. Untreated, diabetic rats were anticipated to have the lowest
tensile strengths of scars while lean rats would have the highest. Diabetic rats treated
with APG were expected to have increased wound tensile strengths compared to diabetic
control rats. But because of the biphasic nature of growth factors, a decrease in tensile
strength of treated, lean rats was acknowledged as a possibility.

Methods
Throughout the two studies described here, the National Research Council’s
guidelines for the care and use of laboratory animals were followed. Twenty-eight
normal male Spraque-Dawley adult rats with weights ranging from 390g to 430g were
used in the first study. They were divided into three groups: ten experimental rats
received APG,ten control rats received sterile saline, and eight donor rats provided the
blood to make the APG.
General anesthesia was induced by Halothane and maintained with Isoflurane To
attain a higher yield, donor blood was drawn from the femoral artery rather than fr.om
direct cardiac puncture used by Knighton et al.(1982). The right groin of each donorrat
was shaved and prepared with 70% ethanol. The right femoral artery was exposed
through an incision along the inguinal fold as depicted

in Figure 1 and described by Blain

and associates (2001). A 0.5 mm catheter was inserted into the proximal end ofthe
femoral artery and was held in place with microsurgical clips until bound by
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microsurgical sutures as shown in Figure 1. The vessel distal to the insertion point was
ligated to prevent downstream blood loss. Approximately 10 ml of whole blood was
drawn from each rat into a standard blood collection container containing citratephosphate-dextrose(CPD)as an anticoagulant. Donor rats were euthanized by CO2
inhalation followed by bilateral
pneumothorax.
Because the small amount
of blood obtained from one rat,
the blood samples were pooled to
allow a sufficient volume of blood
for processing. The blood was
centrifuged separating into
platelet-poor plasma(PPP)on top,
then platelet-rich plasma(PRP),
the buffy coat, and red blood cells
(RBC)on the bottom.
SmartPrep^*^ (Harvest Technologies, Norwell, MA),an autotransfusion machine,was
used because of its ability to process as little as 45 ml of blood compared to standard
machines requiring at least 200 ml.
The PRP and buffy coat were pipetted off and, as described by Knighton et al.
(1982), were mixed with one unit bovine fibrinogen per milliliter ofPRP. A suspension
of thrombin activated by calcium was prepared separately(lU/ml)(Knighton et al.,
1982). The PRP and thrombin-calcium suspension filled separate cylinders ofa double-
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barrel syringe from PRFUZIN,INC. This allowed the PRP and the lysate to mix
instantly when applied to the wound causing the platelet gel to form directly in the bed.
The two cannot be mixed prior to application because the gel forms in seconds.
Following the induction ofgeneral
anesthesia ofthe experimental and control
groups, the dorsum of each rat was shaved
and was prepared with 70% ethanol. A
transverse 4 cm incision, 1 cm caudal to the
base ofthe neck, was made across the
midline through the full thickness ofthe skin
and panniculus camosus as shown in Figure
2 and described by Lineaweaver et al.
(1985). Each experimental wound bed
received 0.5 ml of platelet gel and each
control wound bed received 0.5 ml ofsterile
saline. Immediately,the wounds were
closed with four interrupted 4/0 nylon
sutures. After recovering from anesthesia,
the rats were given standard animal care and were observed for 14 days for signs of
adverse reactions to the treatments such as edema and

erythema at the wound site and for

general behavior changes.
After 14 days, the Spraque-Dawley rats were euthanized.

A 2 cm wide skin strip

transversing the scar was excised as shown in Figure 2. The thickness and the post-
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excision width were recorded and used to calculate cross-sectional area in millimeters.
The sutures were removed from each scar, and the samples were transported to the
tensometer in sterile saline. The load(Newtons)that each scar could withstand was
tested by a tensometer with a 5 kg tension load cell and cross head speed of 10 mm per
minute. The tensile strength (N/mm^),or force required to rupture the scar, was
calculated by dividing the load(N)by the area(mm^)of the sample’s cross-sectional
area.
For all statistical tests, a significance level ofP<0.05 was used. An unpaired,two
tailed student’s T-test was used to compare the Sprague-Dawley data for significance.
In the second study, twenty-eight Zucker obese (fa/fa) rats weighing 425g to 505g
and twenty-eight Zucker lean rats 270g to 323g were used. The homozygous fa/fa
genotype is a genetically obese diabetic rat that models human type 2 diabetes(Peterson
et al., 1990; Smith and Czech, 1983). The Zucker fa/fa rats and the Zucker lean rats were
each divided into three groups similar to the Spraque-Dawley study: ten rats treated with
APG,ten rats received sterile saline as a control, and eight rats supplied whole blood be
processed into APG. The same methods described above for the Spraque-Dawley study
were replicated in both the fa/fa group and the lean group with each its ten experimental
APG rats and ten control saline rats. However,the wounds from both the fat and lean
Zucker groups were harvested at 7 days instead of 14 days.
Raw data for Zucker rat tensile strength not normally distributed, and
root transformation was utilized to normalize the data.

a square

A 2 x 2 factorial analysis of

variance(F-ANOVA)was applied to the transformed data. This test compared the effect
of the type of rat (fat vs. lean), the effect of the treatment(APG vs. control), and the
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interaction of rat type and treatment. Using a Tukey HSD test, a post hoc analysis was
performed on the transformed data to determine the p-values for each ofthe four Zucker
groups. The combination of the F-ANOVA and the post hoc test was chosen over student
t-tests to decrease the chance of Type I error.

Results
After closure of the wounds, no signs of complications or behavioral changes
were observed in any of the animals. On day 14 in the Spraque-Dawley rats and day 7 m
the Zucker rats, both control and treated wounds appeared closed with pink healthy scar
with no evidence of dehiscence or infection. As shown in Table 1, no significant
difference(P= 0.82) was found between the Spraque-Dawley wounds treated with APG
and the controls given saline. Figure 3 graphically depicts the mean tensile strengths and
includes standard error bars.
The Zucker rats’ F-ANOVA,Table 2, revealed that treatment with APG(0.16
N/mm^)significantly decreased (P=0.04) mean tensile strength by 20% compared to the
mean control of0.20 N/mm^. Rat type had no statistically significant effect on tensile
strength. Both obese rats and lean rats averaged 0.19 N/mm^. The mean strength ofthe
control lean wounds was the highest at 0.23 N/mm^ while the APG lean wounds were
39% weaker at 0.14 N/mm^. The APG diabetic wounds were 78% as strong as the
control lean scars and showed 4.3% higher mean strength than untreated diabetic wounds.
With a P-value of0.03, the interaction oftreatment by type also showed significance.
However,these numbers only revealed that a difference existed, and a Post Hoc
test was required to show which groups were statistically different from each other.
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Tukey’s Post Hoc test. Table 3, revealed a significant difference between APG lean and
control lean rats with a P value of0.018, while the other relevant comparisons failed to
demonstrate any statistical differences. Figure 4 graphically depicts these comparisons.

Table 1: Tensile Strength Comparison of Spraque-Dawley Rats.
Eficct
Total
Control
APG

N
20
10
10

Mean Tensile
Strength (N/mm~)
0.60
0.61
0.60

P

SE
0.025
0.034
0.037

0.82

Table 2; F-ANOVA Tensile Strength Comparison ofZucker Rats,Lean and fa/fa.
Effect
Total
Treatment
Treatment
Rat Type
Rat Type
Treat*Type
Treat*Type
Treat*Type
Treat*Type

Level of
Factor

Level of
Factor

N
39
20
19
19
20
10
10
9
10

Control
APG

Lean
fa/fa
Control
Control
APG
APG

Lean
fa/fa
Lean
fa/fa

Mean Tensile
Strength(N/mm^)
0.18
0.20
0.16
0.19
0.17
0.23
0.17
0.14
0.18

SE
0.011
0.013
0.016
0.016
0.015
0.020
0.013
0.013
0.027

P value of
sqrt data
0.04
0.59

0.03

Table 3: Tukey HSD Test Comparing the Significance of Each Group (P<0.05).
1
2
3
4

Treatment
Control
Control
APG
APG

Rat Type
Lean
fa/fa
Lean
fa/fa

1

0.20
0.018
0.22

2

3

0.20

0.018
0.66

0.66
1.00

0.63

4

0.22
1.00 P
0.63
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Figure 3:Tensile Strength in SpraqueDawley Rats
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Discussion
The main value of the Sprague-Dawley pilot lies more in the development ofthe
design and technique for the larger study rather than for the data it produced. The study
demonstrated that for experimental purposes using blood from multiple rats did not
adversely affect the appearance nor the tensile strength ofthe new tissue. Figure 3
illustrates how similar the two groups are. It is not surprising that no statistical difference
was found between the Spraque-Dawley groups as Kiritsy and Lynch(1993)point out
that the effects of additional growth factors are often “muted” in healthy individuals.
However, it is important to note that treatment with APG did not adversely affect tensile
strength in Sprague-Dawley rats as in lean Zucker rats, both non-diabetics.
The reasons for these differences are not clear. Waiting 14 days before sampling
may have allowed enough time for any early differences in treated and control wounds to
even out, while the shorter healing period for the Zucker rats revealed a significant but,
perhaps, temporary effect. This question could be answered by repeating the SpragueDawley study, sampling at 7 days, but sampling Zucker rats at 14 days would provide the
same answer and be more pertinent to the main study.
Since most ofthe growth factors released by APG are short-lived and have their
greatest effect in the few days after they reach the wound,it was reasoned that shortening
the healing time before sampling the Zucker scars would more dramatically reflect any
effect caused by the treatment. The results in Table 2 show that there was no significant
effect of rat type on tensile strength contradicting our prediction that diabetic rats would
have weaker scars than non-diabetic rats. However, each rat type responded differently
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to the treatments indicated in Table 2 by a P-value of0.03 for the treatment by type
interaction.
Untreated diabetic rats did not have the lowest tensile strength as predicted.
Instead, lean rats treated with AGP appeared to lose wound strength, havingl3% less
strength than control diabetic rats when both are compared to mean strength ofthe
control lean group. This marked decrease likely results from the biphasic nature ofthe
grov^ factors described by Kiritsy and Lynch(1993)and Hunt(1990). Fat rats treated
with APG failed to show any substantial difference,improving only 4.3% over control fat
rats. With a P-value of 1.00 in Table 3,these groups are statistically indistinguishable as
Figure 4 clearly shows. APG had no notable effects on the tensile strength ofdiabetic
wounds.
Hunt(1990) points out that a clean, surgical incision followed by immediate
closure is hardly demanding on a body’s repair system where as wounds such as bums
require large scale synthesis of new tissue and “a maximum physiologic response.”
Perhaps a single linear surgical wound is not taxing enough on the animal’s resources for
the treatment to make any sizeable difference in the Spraque-Dawley study or diabetic
Zucker group.
A rat model using an excisional wound would more closely approximate clinical
applications. Platelet gel can be used to treat surgical and other incisional wounds but
most frequently is described in conjunction with wounds such as bums and chronic ulcers
(Knighton et al., 1990). A rat model using an excisional wound would more closely
approximate these clinical applications. Excisional wounds are less conducive for tensile
strength testing but provide a clearer picture of what is changing in the wound when
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histology is analyzed (Kiritsy and Lynch, 1993). This trade-off makes both incisional
and excisional models important to fiilly understanding the effects of APG.
In future studies, each rat could be made a block by producing both APG and
control wounds on the same animal. Blocks will allow for a greater sample size without
involving more animals. The block design for an incisional wound would require
modifying the wound from transversing the midline to one incision on each side ofand
parallel to the midline. This placement on either side ofthe midline will ensure the same
blood supply to each wound. Mustoe and associates(1987) used a similar block design
to study the effects of TGF-p on tensile strength. A block design for an excisional wound
was described by Saba et al.(2002) using four 1-cm^ full-thickness wounds on the
dorsum, one above each shoulder and one above each hip.
Saba et al.(2000) and Knighton et al.(1990)both describe multiple applications
of their treatments while we only used a single application. Multiple treatments would
likely amplify effects in both lean and fat Zucker rats. Ifthe decrease in the control lean
wounds resulted from the biphasic properties of growth factors, it is important to explore
the biphasic threshold of diabetic wounds as well to determine if a succession of
treatments or particular concentration might cross this boundary and become detrimental.
The complexity of healing makes it not only hard to define what is “healed,” but
also to quantify the amount of healing. While clinical anecdotes often focus on decreased
recovery time, this study uses tensile strength as its criterion to judge healing, and as
Ladin (2000)noted in treatments ofchronic wounds,rapid wound healing does not
necessarily equal a strong resilient scar. In chronic diabetic wounds, restoring strength to
prevent reoccurrence ofthe wound is often more important than speedy closure.
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